View Document Preview and Link Document Date: 2013-05-26 22:10:23 Open Document File Size: 1,53 MB Share Result on Facebook
Company Actavis / Makhteshim Agan / Amgen / Starpharma TECHNOLOGY / Valeant Pharmaceuticals International / Pfizer / Ansell / Starpharma Holdings Limited / / Country United States / Australia / United Kingdom / China / / Currency USD / / / Event FDA Phase / Business Partnership / Funding / / Facility Baker IDI Building / / IndustryTerm to dendrimer applications / dendrimer technology / condom product / clinical management / bioluminescent imaging / pharmaceuticals / highvalue applications / drug maker / target pharmaceuticals / manufacturing validation / treatment for the secondary tumours of breast cancer / non-crop protection products / / MedicalCondition viral conjunctivitis / bacterial vaginosis / metastasis / secondary tumours / conjunctivitis / breast cancer / Lung metastases / cancer / recurrent bacterial vaginosis / often difficult chronic condition / metastases / / MedicalTreatment antibiotics / anti-viral therapy / Dendrimer / dendrimers / / Organization Department of Genitourinary Medicine / Royal Hallamshire and Sheffield Teaching Hospitals / FDA / / Person Jackie Fairley / George Kinghorn / Rebecca Wilson / / / Position general public pricing pressures / www.starpharma.com Company Ben Rogers Company Secretary / analyst recommendations / CEO / Professor / expert clinical advisor / Analyst / Clinical Director at NIHR Clinical Research Network / / Product metronidazole / Taxotere / VivaGel® / VivaGel / US1 / / Technology dendrimer technology / antibodies / nanomedicine-based TECHNOLOGY / drug delivery / / URL www.starpharma.com / / SocialTag 
IN THIS ISSUE › VivaGel® update › New agrochemical partnership › SPL7013 shows therapeutic potential in viral conjunctivitis › Positive dendrimerdoxorubicin results